Keytruda Qlex is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute
The goal is to deliver greater value to customers, doctors, and the broader healthcare ecosystem
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
The inspection concluded with zero form 483 observations
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
Encouraging early detection and breaking the silence around men’s health
The hospital was recognised as a Winner (Medium) in the category of Best Academic Institution (Government/Private)
Subscribe To Our Newsletter & Stay Updated
